United States· US:0597-0140_80d5d700-e711-462e-b291-3684a78d00b8

Tradjenta

A linagliptin product containing linagliptin, registered in United States by Boehringer Ingelheim Pharmaceuticals, Inc.. The same ATC class is registered in 17 of our 19 countries.

ATC A10BH05US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedTradjentaATCA10BH05REGISTER NO.US:0597-0140_80d5d700…PACKS LISTED8CHECKEDSeptember 27, 2026

Where it is registered

Linagliptin is registered in 17 of 19 countries.

Countries holding a registration under ATC A10BH05 (linagliptin), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Linagliptin · ATC A10BH05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of linagliptin costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Linagliptin · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • IT Italy$2.52
  • CH Switzerland$2.05
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
LINAGLIPTIN
Manufacturer
Boehringer Ingelheim Pharmaceuticals, Inc.
Country
United States (US)
ATC code
A10BH05
ATC class
Linagliptin
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 8

  • ndc11
    0597014030
    30 TABLET, FILM COATED in 1 BOTTLE (0597-0140-30)
  • ndc11
    0597014061
    100 BLISTER PACK in 1 CARTON (0597-0140-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK
  • ndc11
    0597014070
    7 BLISTER PACK in 1 CARTON (0597-0140-70) / 1 TABLET, FILM COATED in 1 BLISTER PACK
  • ndc11
    0597014090
    90 TABLET, FILM COATED in 1 BOTTLE (0597-0140-90)
  • ndc11
    0597-0140-30
  • ndc11
    0597-0140-61
  • ndc11
    0597-0140-90
  • ndc11
    0597-0140-70

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

373 interactions on record for linagliptin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Linagliptin · interactions on record

373 records

  • 3 severe
  • 330 moderate
  • 40 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Linagliptin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All linagliptin products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Ilinpru, Liamell
  • Belgium · Linagliptin Eg, Linagliptin Eg (Eurogenerics) Nv
  • Bulgaria · Linagliptin Accord, Глунава
  • Cyprus · Glunava, Linagliptin Accord
  • Czechia · Glunava, Jeligo
  • Germany · Linagliptin Abdi
  • Denmark · Linagliptin "pharmapath", Linagliptin Accord
  • Estonia · Glunava, Linagliptin Accord
  • Spain · Donumid, Ilinpru
  • Finland · Linagliptin Accord, Linagliptin Advanz Pharma
  • France · Linagliptine Zentiva
  • United Kingdom (Northern Ireland) · Linagliptin, Linagliptin Altair Science
  • Greece · Bottiar, Drojarto
  • Croatia · Larida, Liglinra
  • Hungary · Ilinpru, Jeligo
  • Ireland · Linagliptin Accord, Linagliptin Clonmel
  • Iceland · Linagliptin Krka, Linagliptin Stada
  • Italy · Linagliptin Abdi, Linagliptin Aurobindo
  • Liechtenstein · Trajenta
  • Lithuania · Bottiar, Jeligo
  • Luxembourg · Linagliptin Eg
  • Latvia · Linagliptin Accord, Linagliptin Olpha
  • Malta · Liamell, Linagliptin
  • Netherlands · Linagliptin Viatris, Linagliptin Vivanta
  • Norway · Linagliptin Accord, Linagliptin Krka
  • Poland · Jeligo, Larida
  • Portugal · Enanta, Larida
  • Romania · Jeligo, Linagliptin Medochemie
  • Sweden · Liglinra, Linagliptin Accord
  • Slovenia · Liglipex, Linagliptin Krka
  • Slovakia · Glunava, Ilinpru

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ceb56bd2-e505-41f0-b491-93d586d0c839
GET /v1/drugs/ceb56bd2-e505-41f0-b491-93d586d0c839?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "5",
  "substance": "LINAGLIPTIN",
  "productndc": "0597-0140",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA201280",
  "marketing_category": "NDA"
}

See everything about linagliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.